{"id":"didanosine","rwe":[{"pmid":"41561667","year":"2026","title":"ABCA4-associated retinopathy complicated by didanosine-associated retinal toxicity.","finding":"","journal":"American journal of ophthalmology case reports","studyType":"Clinical Study"},{"pmid":"41540477","year":"2026","title":"Chronic HIV infection complicated by pancreatitis, pancreatic tail pseudocyst and atraumatic splenic rupture: a case report.","finding":"","journal":"AIDS research and therapy","studyType":"Clinical Study"},{"pmid":"41462126","year":"2025","title":"A systematic review assessing body mass index and waist circumference as predictors for the development of type 2 diabetes mellitus among people living with HIV on antiretroviral therapy.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"},{"pmid":"40818362","year":"2025","title":"Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"40596906","year":"2025","title":"Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission.","finding":"","journal":"BMC infectious diseases","studyType":"Clinical Study"}],"tags":[{"label":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J05AF02","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Human immunodeficiency virus infection","category":"indication"},{"label":"Bristol Myers Squibb","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Anti-HIV Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Anti-Retroviral Agents","category":"pharmacology"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Antiviral Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"},{"label":"Nucleic Acid Synthesis Inhibitors","category":"pharmacology"},{"label":"Reverse Transcriptase Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":1013.123,"date":"","count":343,"signal":"Foetal exposure during pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 343 times (LLR=1013)"},{"llr":916.066,"date":"","count":185,"signal":"Viral mutation identified","source":"DrugCentral FAERS","actionTaken":"Reported 185 times (LLR=916)"},{"llr":889.584,"date":"","count":167,"signal":"Lipodystrophy acquired","source":"DrugCentral FAERS","actionTaken":"Reported 167 times (LLR=890)"},{"llr":879.178,"date":"","count":191,"signal":"Virologic failure","source":"DrugCentral FAERS","actionTaken":"Reported 191 times (LLR=879)"},{"llr":821.957,"date":"","count":145,"signal":"Mitochondrial toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 145 times (LLR=822)"},{"llr":607.142,"date":"","count":144,"signal":"Eyelid ptosis","source":"DrugCentral FAERS","actionTaken":"Reported 144 times (LLR=607)"},{"llr":604.149,"date":"","count":195,"signal":"Drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 195 times (LLR=604)"},{"llr":581.148,"date":"","count":152,"signal":"Pathogen resistance","source":"DrugCentral FAERS","actionTaken":"Reported 152 times (LLR=581)"},{"llr":409.182,"date":"","count":71,"signal":"Progressive external ophthalmoplegia","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=409)"},{"llr":375.737,"date":"","count":129,"signal":"Diplopia","source":"DrugCentral FAERS","actionTaken":"Reported 129 times (LLR=376)"},{"llr":331.439,"date":"","count":46,"signal":"Pinealoblastoma","source":"DrugCentral FAERS","actionTaken":"Reported 46 times (LLR=331)"},{"llr":288.768,"date":"","count":102,"signal":"Pregnancy","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=289)"},{"llr":257.586,"date":"","count":50,"signal":"Retinal toxicity","source":"DrugCentral FAERS","actionTaken":"Reported 50 times (LLR=258)"},{"llr":235.302,"date":"","count":164,"signal":"Treatment failure","source":"DrugCentral FAERS","actionTaken":"Reported 164 times (LLR=235)"},{"llr":187.67,"date":"","count":52,"signal":"Hepatic fibrosis","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=188)"}],"drugInteractions":[{"url":"/drug/enoxacin","drug":"enoxacin","action":"Monitor closely","effect":"May interact with Enoxacin","source":"DrugCentral","drugSlug":"enoxacin"},{"url":"/drug/ganciclovir","drug":"ganciclovir","action":"Monitor closely","effect":"May interact with Ganciclovir","source":"DrugCentral","drugSlug":"ganciclovir"},{"url":"/drug/indinavir","drug":"indinavir","action":"Monitor closely","effect":"May interact with Indinavir Sulfate","source":"DrugCentral","drugSlug":"indinavir"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Monitor closely","effect":"May interact with Itraconazole","source":"DrugCentral","drugSlug":"itraconazole"},{"url":"/drug/ketoconazole","drug":"ketoconazole","action":"Monitor closely","effect":"May interact with Ketoconazole","source":"DrugCentral","drugSlug":"ketoconazole"},{"url":"/drug/lomefloxacin","drug":"lomefloxacin","action":"Monitor closely","effect":"May interact with Lomefloxacin","source":"DrugCentral","drugSlug":"lomefloxacin"},{"url":"/drug/methadone","drug":"methadone","action":"Monitor closely","effect":"May interact with Methadone","source":"DrugCentral","drugSlug":"methadone"},{"url":"/drug/norfloxacin","drug":"norfloxacin","action":"Monitor closely","effect":"May interact with Norfloxacin","source":"DrugCentral","drugSlug":"norfloxacin"},{"url":"/drug/ofloxacin","drug":"ofloxacin","action":"Monitor closely","effect":"May interact with Ofloxacin","source":"DrugCentral","drugSlug":"ofloxacin"},{"url":"/drug/pentamidine","drug":"pentamidine","action":"Monitor closely","effect":"May interact with Pentamidine","source":"DrugCentral","drugSlug":"pentamidine"},{"url":"/drug/ribavirin","drug":"ribavirin","action":"Avoid combination","effect":"May interact with Ribavirin","source":"DrugCentral","drugSlug":"ribavirin"},{"url":"/drug/tenofovir","drug":"tenofovir","action":"Monitor closely","effect":"May interact with Tenofovir","source":"DrugCentral","drugSlug":"tenofovir"},{"url":"/drug/tetracycline","drug":"tetracycline","action":"Monitor closely","effect":"May interact with Tetracycline","source":"DrugCentral","drugSlug":"tetracycline"},{"url":"/drug/tipranavir","drug":"tipranavir","action":"Monitor closely","effect":"May interact with Tipranavir","source":"DrugCentral","drugSlug":"tipranavir"},{"url":"/drug/zalcitabine","drug":"zalcitabine","action":"Monitor closely","effect":"DIDANOSINE/ZALCITABINE (DIDEOXYCYTIDINE,ddC)","source":"DrugCentral","drugSlug":"zalcitabine"}],"commonSideEffects":[{"effect":"Pancreatitis","drugRate":"10%","severity":"serious","organSystem":""},{"effect":"Pancreatitis","drugRate":"7%","severity":"serious","organSystem":""},{"effect":"Pancreatitis","drugRate":"3%","severity":"serious","organSystem":""},{"effect":"Pancreatitis","drugRate":"1%","severity":"serious","organSystem":""}],"contraindications":["Acute nephropathy","Adrenal cortical hypofunction","Alcoholism","Aluminum intoxication","Anuria","Azotemia","Breastfeeding (mother)","Cardiovascular event risk","Chronic diarrhea","Chronic heart failure","Constipation","Dehydration","Diabetes mellitus","Diarrhea","Disease of liver","Disorder of coronary artery","Familial hyperkalemic periodic paralysis","Fecal impaction","Gastrointestinal obstruction","Hemorrhoids","Hypercalcemia","Hypercholesterolemia","Hyperkalemia","Hypernatremia","Hyperparathyroidism"],"specialPopulations":{"Pregnancy":"Fatal lactic acidosis has been reported in pregnant women who received both didanosine and stavudine with other agents. This combination should be used with caution during pregnancy and only if the potential benefit clearly outweighs the potential risk. Reproduction studies have been performed in rats and rabbits at doses up to 12 and 14.2 times the estimated human exposure (based upon plasma levels), respectively, and have revealed no evidence of impaired fertility or harm to the fetus due to didanosine. There are no adequate and well-controlled studies of didanosine in pregnant women. Didanosine should be used during pregnancy only if the potential benefit justifies the potential risk.","Geriatric use":"In an Expanded Access Program using buffered formulation of didanosine for the treatment of advanced HIV infection, patients aged 65 years and older had higher frequency of pancreatitis (10%) than younger patients (5%).","Paediatric use":"Use of didanosine in pediatric patients from weeks of age through adolescence is supported by evidence from adequate and well-controlled studies of didanosine in adult and pediatric patients. Additional pharmacokinetic studies in pediatric patients support use of didanosine in pediatric patients who weigh at least 20 kg."},"seriousAdverseEvents":[{"effect":"Pancreatitis (fatal)","drugRate":"2.94%","severity":"serious"},{"effect":"Pancreatitis (fatal)","drugRate":"1.47%","severity":"serious"},{"effect":"Pancreatitis (pediatric, higher doses)","drugRate":"13%","severity":"serious"},{"effect":"Pancreatitis (pediatric, lower doses)","drugRate":"3%","severity":"serious"},{"effect":"Lactic acidosis/symptomatic hyperlactatemia","drugRate":"","severity":"serious"},{"effect":"Liver failure","drugRate":"","severity":"serious"},{"effect":"Hepatic steatosis","drugRate":"","severity":"serious"},{"effect":"Portal hypertension (non-cirrhotic)","drugRate":"","severity":"serious"},{"effect":"Hepatitis","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid reaction","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"company":"Bristol-Myers Squibb","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DIDANOSINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:16:20.454901+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:16:27.232918+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIDANOSINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:16:28.030139+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Human immunodeficiency virus type 1 reverse transcriptase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:30.638210+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1460/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:16:30.393331+00:00"}},"allNames":"videx","offLabel":[],"synonyms":["didanosine","videx","dideoxyinosine"],"timeline":[{"date":"1991-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BRISTOL MYERS SQUIBB to Bristol Myers Squibb"},{"date":"1991-10-09","type":"positive","source":"DrugCentral","milestone":"FDA approval (Bristol Myers Squibb)"},{"date":"2000-10-31","type":"positive","source":"FDA Orange Book","milestone":"Videx Ec approved — 125MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**"},{"date":"2010-04-08","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"}],"aiSummary":"Videx (didanosine) is a small molecule nucleoside analog reverse transcriptase inhibitor developed by Bristol Myers Squibb, currently owned by the same company. It was FDA-approved in 1991 for the treatment of human immunodeficiency virus (HIV) infection. Videx is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 1.4 hours and variable bioavailability of 38%. As an off-patent medication, Videx is widely available in generic forms.","approvals":[{"date":"1991-10-09","orphan":false,"company":"BRISTOL MYERS SQUIBB","regulator":"FDA"}],"brandName":"Videx","ecosystem":[{"indication":"Human immunodeficiency virus infection","otherDrugs":[{"name":"abacavir","slug":"abacavir","company":"Viiv Hlthcare"},{"name":"amprenavir","slug":"amprenavir","company":"Glaxosmithkline"},{"name":"atazanavir","slug":"atazanavir","company":"Bristol Myers Squibb"},{"name":"bictegravir","slug":"bictegravir","company":"Gilead Sciences Inc"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Nucleoside Reverse Transcriptase Inhibitors","modality":"Small Molecule","drugClass":"Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Videx (didanosine) is a nucleoside analog reverse transcriptase inhibitor that acts as a chain terminator of DNA synthesis, thereby inhibiting the replication of HIV by competing with natural nucleosides for incorporation into viral DNA."},"commercial":{"launchDate":"1991","_launchSource":"DrugCentral (FDA 1991-10-09, BRISTOL MYERS SQUIBB)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/869","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIDANOSINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIDANOSINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:34:54.858076","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:32.377743+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"zidovudine","drugSlug":"zidovudine","fdaApproval":"1987-03-19","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"zalcitabine","drugSlug":"zalcitabine","fdaApproval":"1992-06-19","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"stavudine","drugSlug":"stavudine","fdaApproval":"1994-06-24","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lamivudine","drugSlug":"lamivudine","fdaApproval":"1995-11-17","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"abacavir","drugSlug":"abacavir","fdaApproval":"1998-12-17","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"tenofovir disoproxil","drugSlug":"tenofovir-disoproxil","fdaApproval":"2001-10-26","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"adefovir dipivoxil","drugSlug":"adefovir-dipivoxil","fdaApproval":"2002-09-20","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"emtricitabine","drugSlug":"emtricitabine","fdaApproval":"2003-07-02","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"entecavir","drugSlug":"entecavir","fdaApproval":"2005-03-29","genericCount":17,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"telbivudine","drugSlug":"telbivudine","fdaApproval":"2006-10-25","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"tenofovir alafenamide","drugSlug":"tenofovir-alafenamide","fdaApproval":"2015-11-05","patentExpiry":"Feb 15, 2033","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"didanosine","indications":{"approved":[{"name":"Human immunodeficiency virus infection","source":"DrugCentral","snomedId":86406008,"regulator":"FDA","eligibility":"No specific patient eligibility criteria mentioned"}],"offLabel":[{"name":"Prevention of HIV Infection after Exposure","source":"DrugCentral","drugName":"DIDANOSINE","evidenceCount":22,"evidenceLevel":"moderate"}],"pipeline":[]},"currentOwner":"Bristol Myers Squibb","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"zidovudine","brandName":"zidovudine","genericName":"zidovudine","approvalYear":"1987","relationship":"same-class"},{"drugId":"zalcitabine","brandName":"zalcitabine","genericName":"zalcitabine","approvalYear":"1992","relationship":"same-class"},{"drugId":"stavudine","brandName":"stavudine","genericName":"stavudine","approvalYear":"1994","relationship":"same-class"},{"drugId":"lamivudine","brandName":"lamivudine","genericName":"lamivudine","approvalYear":"1995","relationship":"same-class"},{"drugId":"abacavir","brandName":"abacavir","genericName":"abacavir","approvalYear":"1998","relationship":"same-class"},{"drugId":"tenofovir-disoproxil","brandName":"tenofovir disoproxil","genericName":"tenofovir disoproxil","approvalYear":"2001","relationship":"same-class"},{"drugId":"adefovir-dipivoxil","brandName":"adefovir dipivoxil","genericName":"adefovir dipivoxil","approvalYear":"2002","relationship":"same-class"},{"drugId":"emtricitabine","brandName":"emtricitabine","genericName":"emtricitabine","approvalYear":"2003","relationship":"same-class"},{"drugId":"entecavir","brandName":"entecavir","genericName":"entecavir","approvalYear":"2005","relationship":"same-class"},{"drugId":"telbivudine","brandName":"telbivudine","genericName":"telbivudine","approvalYear":"2006","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2,PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":["Acquired Immune Deficiency Syndrome (AIDS)","HIV Infections"],"enrollment":133,"completionDate":"2027-03"},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":["HIV-1-infection"],"enrollment":350,"completionDate":"2034-03"},{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":["HIV Infections"],"enrollment":500,"completionDate":"2024-09-12"},{"nctId":"NCT05633147","phase":"PHASE1","title":"Effect of Clarithromycin on PK of Linaprazan, Linaprazan on PK of Clarithromycin and Linaprazan on PK of Midazolam","status":"COMPLETED","sponsor":"Cinclus Pharma Holding AB","startDate":"2022-11-27","conditions":["Safety Issues","Pharmacokinetics","Drug Interaction","Tolerability"],"enrollment":35,"completionDate":"2023-05-30"},{"nctId":"NCT01605084","phase":"PHASE3","title":"Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2012-06-30","conditions":["HIV"],"enrollment":0,"completionDate":"2014-08-31"},{"nctId":"NCT00955968","phase":"PHASE4","title":"IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women","status":"COMPLETED","sponsor":"International Maternal Pediatric Adolescent AIDS Clinical Trials Group","startDate":"2010-01-01","conditions":["HIV Infection"],"enrollment":1653,"completionDate":"2016-08-31"},{"nctId":"NCT00109590","phase":"PHASE2","title":"Reducing the Incidence of Nevirapine Resistance Mutations in Pregnant HIV Infected Women Who Receive Anti-HIV Drugs Prior to and After Giving Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-06","conditions":["HIV Infections"],"enrollment":175,"completionDate":"2009-11"},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":["HIV Infections"],"enrollment":3526,"completionDate":"2015-05"},{"nctId":"NCT00016718","phase":"PHASE1,PHASE2","title":"Safety and Effectiveness of Emtricitabine, Efavirenz, and Didanosine in HIV Infected Children Who Have Taken Few or No Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2001-08","conditions":["HIV Infections"],"enrollment":43,"completionDate":"2009-01"},{"nctId":"NCT00000710","phase":"PHASE1","title":"A Phase I Safety, Efficacy, and Pharmacokinetic Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Patients With AIDS or AIDS Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":42,"completionDate":"1990-05"},{"nctId":"NCT00001045","phase":"PHASE2","title":"Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients With No Symptoms of the Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1998-10"},{"nctId":"NCT00000891","phase":"PHASE2","title":"Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":34,"completionDate":"2004-05"},{"nctId":"NCT00001068","phase":"PHASE2","title":"A Study of Disease Progression and Anti-HIV Treatments","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":210,"completionDate":"1998-10"},{"nctId":"NCT00000810","phase":"PHASE1","title":"Randomized, Phase I/II, Dose-Ranging, Open-Label Trial of the Anti-HIV Activity of Delavirdine Mesylate (DLV; U-90,152S)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":120,"completionDate":"1996-01"},{"nctId":"NCT00000831","phase":"PHASE2","title":"Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":280,"completionDate":"1998-05"},{"nctId":"NCT00000851","phase":"PHASE2","title":"Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":198,"completionDate":"1998-10"},{"nctId":"NCT00000753","phase":"PHASE1","title":"A Phase I Concentration-Targeted Multidose Study of Atevirdine Mesylate ( U-87201E ), AZT, and ddI or ddC","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":30,"completionDate":"1995-02"},{"nctId":"NCT00001029","phase":"PHASE2","title":"A Comparison of Three Treatments for Advanced HIV Disease in Patients Who Have Received Nucleoside Therapy in the Past","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":654,"completionDate":"1993-05"},{"nctId":"NCT00001063","phase":"PHASE2","title":"The Effectiveness of Three Drug Combinations in HIV-Infected Patients Who Have Taken Zidovudine for More Than 12 Weeks","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":"1997-11"},{"nctId":"NCT00000838","phase":"PHASE2","title":"Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":256,"completionDate":"1998-03"},{"nctId":"NCT00001022","phase":"PHASE3","title":"A Comparison of Zidovudine (AZT) Used Alone or in Combination With Didanosine (ddI) or Dideoxycytidine (ddC) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1200,"completionDate":"1995-12"},{"nctId":"NCT00000781","phase":"PHASE2","title":"A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, and Triple-Drug Therapy for the Treatment of Advanced HIV Disease (CD4 <= 50/mm3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1292,"completionDate":"1996-09"},{"nctId":"NCT00000742","phase":"PHASE1","title":"A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":15,"completionDate":"1993-10"},{"nctId":"NCT00000969","phase":"NA","title":"A Prospective, Randomized, Open-Label, Comparative Trial of Dideoxyinosine (ddI) Versus Dideoxycytidine (ddC) in HIV-Infected Patients Who Are Intolerant of or Who Have Failed Zidovudine (AZT) Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":400,"completionDate":"1992-09"},{"nctId":"NCT00000803","phase":"PHASE2","title":"A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":471,"completionDate":"1997-03"},{"nctId":"NCT00000770","phase":"PHASE2","title":"A Comparative Study of a Combination of Zidovudine, Didanosine, and Double-Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":400,"completionDate":"1994-11"},{"nctId":"NCT00000657","phase":"PHASE2","title":"Comparison of 2',3'-Dideoxyinosine (Didanosine, ddI) and Zidovudine in Therapy of Patients With the AIDS Dementia Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["AIDS Dementia Complex","HIV Infections"],"enrollment":80,"completionDate":"1992-09"},{"nctId":"NCT00000656","phase":"PHASE1","title":"A Phase I/II, Open Label Study to Evaluate the Antiviral Potential of Combination Zidovudine and 2' 3'-Dideoxyinosine (Didanosine) in Patients With Asymptomatic HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":116,"completionDate":"1993-11"},{"nctId":"NCT00000637","phase":"PHASE3","title":"A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":819,"completionDate":"1996-09"},{"nctId":"NCT00102960","phase":"PHASE3","title":"Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-07","conditions":["HIV Infections"],"enrollment":377,"completionDate":"2013-01"},{"nctId":"NCT00000625","phase":"PHASE2","title":"A Randomized, Double-Blind Phase II/III Trial of Monotherapy vs. Combination Therapy With Nucleoside Analogs in HIV-Infected Persons With CD4 Cells of 200-500/mm3","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":2100,"completionDate":"1995-11"},{"nctId":"NCT00001024","phase":"NA","title":"The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":32,"completionDate":"2002-06"},{"nctId":"NCT00001114","phase":"PHASE2","title":"The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Sarcoma, Kaposi","HIV Infections"],"enrollment":90,"completionDate":"2000-03"},{"nctId":"NCT00007202","phase":"PHASE2","title":"Safety and Effectiveness of a Three-Drug Combination Treatment for Recently Infected or Converted HIV Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":55,"completionDate":"2006-10"},{"nctId":"NCT00001057","phase":"PHASE2","title":"The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":105,"completionDate":"1995-05"},{"nctId":"NCT00051090","phase":"NA","title":"Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Hepatitis B"],"enrollment":0,"completionDate":""},{"nctId":"NCT00001025","phase":"PHASE2","title":"Evaluation of Patients Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":120,"completionDate":"1995-05"},{"nctId":"NCT00001108","phase":"PHASE1","title":"A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":6,"completionDate":"2000-06"},{"nctId":"NCT00001048","phase":"PHASE2","title":"Comparison of Anti HIV Drugs Used Alone or in Combination With Cytosine Arabinoside to Treat Progressive Multifocal Leukoencephalopathy (PML) in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Leukoencephalopathy, Progressive Multifocal"],"enrollment":90,"completionDate":"1997-04"},{"nctId":"NCT00008866","phase":"PHASE2","title":"Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00001074","phase":"PHASE1","title":"The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":140,"completionDate":"2000-01"},{"nctId":"NCT00006339","phase":"PHASE2","title":"Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection","status":"WITHDRAWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":""},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"2000-07"},{"nctId":"NCT00001049","phase":"PHASE1","title":"A Study of Didanosine Use Alone or in Combination With Zidovudine in Infants Exposed to or Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":180,"completionDate":"1998-06"},{"nctId":"NCT00000822","phase":"PHASE1","title":"A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":46,"completionDate":"1999-05"},{"nctId":"NCT00000839","phase":"PHASE1","title":"A Phase I Trial to Evaluate Didanosine (ddI) in HIV-Infected Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Pregnancy"],"enrollment":12,"completionDate":"2001-06"},{"nctId":"NCT00000963","phase":"PHASE2","title":"A Study of Dideoxyinosine (ddI) in HIV-Infected Children Who Have Not Had Success With Zidovudine or Who Cannot Take Zidovudine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1995-09"},{"nctId":"NCT00000954","phase":"PHASE1","title":"A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Sarcoma, Kaposi","HIV Infections"],"enrollment":72,"completionDate":"1996-09"},{"nctId":"NCT00000916","phase":"PHASE2","title":"A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":399,"completionDate":"2004-08"},{"nctId":"NCT00000924","phase":"PHASE2","title":"A Study to Compare Two Different Anti-HIV Drug Regimens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":120,"completionDate":"2001-06"},{"nctId":"NCT00000902","phase":"PHASE1","title":"A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":217,"completionDate":"2002-04"},{"nctId":"NCT00000939","phase":"PHASE2","title":"A Study to Compare the Effectiveness of Different Anti-HIV Drug Regimens in Keeping Levels of HIV in the Blood as Low as Possible","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":150,"completionDate":"2000-01"},{"nctId":"NCT00000865","phase":"PHASE1","title":"The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":32,"completionDate":"1998-04"},{"nctId":"NCT00000772","phase":"PHASE1","title":"A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":15,"completionDate":"1995-02"},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":440,"completionDate":"2003-06"},{"nctId":"NCT00000823","phase":"PHASE2","title":"A Multicenter Phase II Double-Blind Exploratory Study to Evaluate Differences Among Various Zidovudine/Didanosine Regimens on Quantitative Measures of Viral Burden in Relatively Early HIV-1 Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":85,"completionDate":"2000-02"},{"nctId":"NCT00000833","phase":"PHASE1","title":"A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":20,"completionDate":"1998-07"},{"nctId":"NCT00000814","phase":"PHASE1","title":"A Comparative Study of Combination Antiretroviral Therapy in Children and Adolescents With Advanced HIV Disease","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":390,"completionDate":"1998-11"},{"nctId":"NCT00084136","phase":"PHASE4","title":"Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-05","conditions":["HIV Infections"],"enrollment":1571,"completionDate":"2010-05"},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":["HIV Infections"],"enrollment":34,"completionDate":"2009-12"},{"nctId":"NCT00928187","phase":"PHASE3","title":"Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-11","conditions":["HIV","HIV Infections"],"enrollment":454,"completionDate":"2015-12"},{"nctId":"NCT01440569","phase":"PHASE3","title":"Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-09","conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"enrollment":314,"completionDate":"2015-10"},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":["HIV Infection"],"enrollment":724,"completionDate":"2015-04"},{"nctId":"NCT01363011","phase":"PHASE3","title":"Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-05","conditions":["Acquired Immunodeficiency Syndrome","HIV Infections"],"enrollment":106,"completionDate":"2015-02"},{"nctId":"NCT00338390","phase":"PHASE3","title":"Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC","status":"COMPLETED","sponsor":"Hospital de Granollers","startDate":"2005-04","conditions":["HIV Infections"],"enrollment":75,"completionDate":"2007-02"},{"nctId":"NCT02251873","phase":"PHASE1","title":"Evaluation of the Pharmacokinetic Interaction of Steady State Tipranavir and Ritonavir or Tipranavir and Ritonavir With Single Dose Didanosine in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2001-09","conditions":["Healthy"],"enrollment":50,"completionDate":""},{"nctId":"NCT00364793","phase":"PHASE1,PHASE2","title":"Safety, Tolerability and Pharmacokinetics of Efavirenz in HIV-Infected Children","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2007-02","conditions":["HIV Infections"],"enrollment":56,"completionDate":"2013-07"},{"nctId":"NCT00000922","phase":"NA","title":"A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1710,"completionDate":"2006-06"},{"nctId":"NCT00002905","phase":"PHASE2","title":"Combination Chemotherapy in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma","status":"UNKNOWN","sponsor":"Centro di Riferimento Oncologico - Aviano","startDate":"1995-06","conditions":["Lymphoma"],"enrollment":20,"completionDate":""},{"nctId":"NCT00006154","phase":"PHASE3","title":"A Study to Evaluate the Use of a Protease Inhibitor and of Interleukin-2 (IL-2) in the Treatment of Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":165,"completionDate":""},{"nctId":"NCT00014937","phase":"NA","title":"Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":240,"completionDate":""},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":["HIV"],"enrollment":1771,"completionDate":"2008-08"},{"nctId":"NCT00000652","phase":"PHASE1","title":"A Phase I Study to Evaluate the Safety and Toxicity of the Combination of Zidovudine and 2',3'-Dideoxyinosine (Didanosine) in Children With HIV Infection","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"","conditions":["HIV Infections"],"enrollment":85,"completionDate":"1995-11"},{"nctId":"NCT00703586","phase":"PHASE1","title":"Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2007-09","conditions":["HIV Infections"],"enrollment":8,"completionDate":"2011-05"},{"nctId":"NCT00197613","phase":"PHASE3","title":"The Adult Antiretroviral Treatment and Resistance Study (Tshepo)","status":"COMPLETED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2002-12","conditions":["AIDS","HIV Infection"],"enrollment":650,"completionDate":"2007-12"},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":900,"completionDate":"2002-11"},{"nctId":"NCT00000870","phase":"PHASE2","title":"A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":200,"completionDate":"2007-03"},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"2002-02"},{"nctId":"NCT00000923","phase":"NA","title":"Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":110,"completionDate":"2004-08"},{"nctId":"NCT00013520","phase":"PHASE3","title":"Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":1125,"completionDate":"2005-06"},{"nctId":"NCT00034086","phase":"NA","title":"Study of Anti-HIV Therapy Intensification","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":22,"completionDate":"2006-06"},{"nctId":"NCT00001035","phase":"PHASE1","title":"The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Hepatitis C"],"enrollment":10,"completionDate":"1996-09"},{"nctId":"NCT00192660","phase":"PHASE4","title":"HIV Infection And Metabolic Abnormalities Protocol 1 (HAMA001)","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2003-02","conditions":["HIV-Associated Lipodystrophy Syndrome","Cardiovascular Disease"],"enrollment":80,"completionDate":"2007-12"},{"nctId":"NCT00142337","phase":"PHASE2","title":"One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine","status":"COMPLETED","sponsor":"Institut de Recherche pour le Developpement","startDate":"2004-12","conditions":["HIV Infections"],"enrollment":244,"completionDate":"2009-02"},{"nctId":"NCT00122538","phase":"PHASE2","title":"Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2006-02","conditions":["HIV Infections","AIDS"],"enrollment":52,"completionDate":"2009-05"},{"nctId":"NCT00002035","phase":"NA","title":"Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":["HIV Infections"],"enrollment":300,"completionDate":"1992-04"},{"nctId":"NCT00002280","phase":"NA","title":"A Study of ddI in Children With AIDS Who Have Not Had Success With Zidovudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"","conditions":["HIV Infections"],"enrollment":0,"completionDate":"1994-11"},{"nctId":"NCT00002240","phase":"PHASE2","title":"Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2001-12"},{"nctId":"NCT00002429","phase":"PHASE3","title":"Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-07","conditions":["HIV Infections"],"enrollment":500,"completionDate":"2001-01"},{"nctId":"NCT00002224","phase":"PHASE3","title":"Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":120,"completionDate":"1999-03"},{"nctId":"NCT00002411","phase":"NA","title":"A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1998-03","conditions":["HIV Infections"],"enrollment":0,"completionDate":"1999-09"},{"nctId":"NCT00002207","phase":"NA","title":"A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-02","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2004-02"},{"nctId":"NCT00116415","phase":"NA","title":"DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2002-03","conditions":["HIV Infections","AIDS"],"enrollment":65,"completionDate":"2004-11"},{"nctId":"NCT00207168","phase":"PHASE4","title":"To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2004-04","conditions":["AIDS"],"enrollment":120,"completionDate":"2006-12"},{"nctId":"NCT00002177","phase":"NA","title":"A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1997-05","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2000-03"},{"nctId":"NCT00002360","phase":"PHASE1","title":"A Study Comparing Two Forms of Didanosine in HIV-infected Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1999-03","conditions":["HIV Infections"],"enrollment":30,"completionDate":"1999-03"},{"nctId":"NCT00002176","phase":"NA","title":"A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"1997-05","conditions":["HIV Infections"],"enrollment":0,"completionDate":"2000-03"},{"nctId":"NCT00000982","phase":"PHASE2","title":"A Study of Azidothymidine in HIV-Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["Encephalopathies","HIV Infections"],"enrollment":75,"completionDate":""},{"nctId":"NCT00000672","phase":"PHASE2","title":"An Efficacy Study of 2',3'-Dideoxyinosine (ddI) (BMY-40900) Administered Orally Twice Daily to Zidovudine Intolerant Patients With AIDS or AIDS-Related Complex","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections"],"enrollment":660,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule","formulations":[{"form":"CAPSULE, DELAYED RELEASE PELLETS","route":"ORAL","productName":"Didanosine"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148104","MMSL":"4588","NDDF":"003604","UNII":"K3GDH6OH08","VUID":"4020118","CHEBI":"CHEBI:490877","VANDF":"4020118","INN_ID":"6664","RXNORM":"152494","UMLSCUI":"C0012133","chemblId":"CHEMBL1460","ChEMBL_ID":"CHEMBL1460","KEGG_DRUG":"D00296","DRUGBANK_ID":"DB00900","PDB_CHEM_ID":" 2DI","PUBCHEM_CID":"135398739","SNOMEDCT_US":"19194001","IUPHAR_LIGAND_ID":"4833","MESH_DESCRIPTOR_UI":"D016049"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1991-","companyName":"Bristol-Myers Squibb","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.4 hours","clearance":"11.0 mL/min/kg","bioavailability":"38%","fractionUnbound":"0.95%","volumeOfDistribution":"0.77 L/kg"},"publicationCount":1933,"therapeuticAreas":["Immunology"],"atcClassification":{"source":"DrugCentral","atcCode":"J05AF02","allCodes":["J05AF02"]},"biosimilarFilings":[],"originalDeveloper":"Bristol Myers Squibb","recentPublications":[{"date":"2026 Mar","pmid":"41561667","title":"ABCA4-associated retinopathy complicated by didanosine-associated retinal toxicity.","journal":"American journal of ophthalmology case reports"},{"date":"2026 Jan 15","pmid":"41540477","title":"Chronic HIV infection complicated by pancreatitis, pancreatic tail pseudocyst and atraumatic splenic rupture: a case report.","journal":"AIDS research and therapy"},{"date":"2025 Dec 29","pmid":"41462126","title":"A systematic review assessing body mass index and waist circumference as predictors for the development of type 2 diabetes mellitus among people living with HIV on antiretroviral therapy.","journal":"BMC infectious diseases"},{"date":"2025 Oct","pmid":"40818362","title":"Unravelling drug-induced hepatic steatosis: Clinical sub-phenotypes, outcome prediction, and identification of high-concern drugs and hazardous chemical attributes.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2025 Jul 1","pmid":"40596906","title":"Drug resistance mutations and phylogenetic analysis of HIV-1 subtypes B and F from mothers and children with vertical transmission.","journal":"BMC infectious diseases"}],"companionDiagnostics":[],"genericManufacturers":4,"_genericFilersChecked":true,"genericManufacturerList":["Aurobindo","Aurobindo Pharma","Barr","Pharmobedient"],"status":"approved","companyName":"Bristol Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"1991","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-10-09T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":"VIDEX","application_number":"NDA020155"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-10-09T00:00:00.000Z","mah":"BRISTOL MYERS SQUIBB","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1991-10-09T00:00:00.000Z","mah":"BRISTOL","brand_name_local":"VIDEX","application_number":"NDA020156"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2004-12-03T00:00:00.000Z","mah":"BARR","brand_name_local":"DIDANOSINE","application_number":"ANDA077167"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2007-03-08T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":"DIDANOSINE","application_number":"ANDA078112"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2008-09-24T00:00:00.000Z","mah":"AUROBINDO PHARMA","brand_name_local":"DIDANOSINE","application_number":"ANDA090094"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-04-08T00:00:00.000Z","mah":"PHARMOBEDIENT","brand_name_local":"DIDANOSINE","application_number":"ANDA090788"},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:16:32.377743+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}